According to the latest National Alliance of Healthcare Purchaser Coalitions survey, 31% of U.S. employers have chosen a transparent pharmacy benefit manager (PBM) – that's up from 12% in 2024. This increase reflects a major industry shift. In just one year, employer contracts with the “Big Three” PBMs...
On August 28, 2025, the US Food and Drug Administration (FDA) approved Teva Pharmaceuticals’ generic to Novo Nordisk’s Saxenda® (liraglutide injection). This is the first generic glucagon-like peptide-1 (GLP-1) agonist approved for use as an adjunct to diet and exercise for chronic weight management...
On August 27, 2025, the FDA approved the 2025-2026 formulas of four COVID-19 vaccines and revoked emergency use authorizations (EUAs) for all COVID-19 vaccines. The new limitations for the COVID-19 vaccines mean that individuals...
Studies show that GLP-1's may improve the mental wellbeing of patients with diabetes and/or obesity. Patients using a GLP-1 might see improvements in the quality of life both physically and mentally. It is suspected that GLP-1's may have an impact on patients with...
The FDA recently granted approval to Novo Nordisk’s Wegovy (semaglutide) for the treatment of noncirrhotic metabolic dysfunction–associated steatohepatitis (MASH). Approximately 6% of U.S. adults (14.9 million people) have MASH (formerly known as nonalcoholic steatohepatitis [NASH]), and its prevalence is growing...
